Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by ING Groep NV

ING Groep NV reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 84.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,637 shares of the medical equipment provider's stock after selling 90,246 shares during the quarter. ING Groep NV's holdings in Zimmer Biomet were worth $1,796,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in ZBH. Empowered Funds LLC increased its stake in Zimmer Biomet by 50.6% during the first quarter. Empowered Funds LLC now owns 3,757 shares of the medical equipment provider's stock valued at $496,000 after purchasing an additional 1,262 shares during the last quarter. Bleakley Financial Group LLC raised its holdings in shares of Zimmer Biomet by 6.2% in the 1st quarter. Bleakley Financial Group LLC now owns 2,271 shares of the medical equipment provider's stock worth $300,000 after purchasing an additional 132 shares in the last quarter. Kingsview Wealth Management LLC boosted its position in shares of Zimmer Biomet by 22.4% in the 1st quarter. Kingsview Wealth Management LLC now owns 3,225 shares of the medical equipment provider's stock valued at $426,000 after purchasing an additional 590 shares during the period. Blair William & Co. IL raised its stake in Zimmer Biomet by 3.7% during the 1st quarter. Blair William & Co. IL now owns 33,364 shares of the medical equipment provider's stock valued at $4,403,000 after purchasing an additional 1,184 shares during the period. Finally, M&G Plc purchased a new stake in shares of Zimmer Biomet in the first quarter worth approximately $7,397,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Trading Up 3.4 %

Shares of NYSE ZBH opened at $112.54 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90. The stock has a market capitalization of $22.40 billion, a P/E ratio of 21.40, a PEG ratio of 2.07 and a beta of 1.02. The business's 50 day moving average is $106.28 and its two-hundred day moving average is $110.04.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts' consensus estimates of $1.74. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company's quarterly revenue was up 4.1% compared to the same quarter last year. During the same period last year, the company posted $1.65 earnings per share. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.85%. The ex-dividend date of this dividend was Monday, September 30th. Zimmer Biomet's payout ratio is currently 18.25%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ZBH. Royal Bank of Canada increased their price objective on Zimmer Biomet from $120.00 to $125.00 and gave the company an "outperform" rating in a report on Monday, November 4th. Wolfe Research assumed coverage on Zimmer Biomet in a research report on Tuesday, September 10th. They issued a "peer perform" rating for the company. UBS Group decreased their price target on Zimmer Biomet from $112.00 to $107.00 and set a "sell" rating on the stock in a report on Thursday, August 8th. Robert W. Baird reduced their price objective on shares of Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating on the stock in a research note on Thursday, August 8th. Finally, Raymond James lowered their price objective on shares of Zimmer Biomet from $128.00 to $123.00 and set an "outperform" rating for the company in a research report on Monday, October 14th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $123.22.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.